Management of Simple Endometrial Hyperplasia Without Atypia in a 46-Year-Old
For a 46-year-old woman with simple endometrial hyperplasia without atypia, progestin therapy is the recommended treatment, with the levonorgestrel-releasing intrauterine system (LNG-IUS) preferred over oral progestins due to superior regression rates, lower recurrence rates, and fewer adverse effects. 1
Treatment Approach
First-Line Medical Management
The evidence strongly supports progestin-based therapy as the standard treatment for endometrial hyperplasia without atypia:
Oral progestins are an alternative if LNG-IUS is contraindicated or declined 3
- Medroxyprogesterone acetate (MPA) 10-20 mg daily
- Megestrol acetate (MA) 40-160 mg daily
- Less effective than LNG-IUS with higher recurrence rates 1
Monitoring Protocol
During treatment, perform endometrial sampling every 6 months to assess response 3, 1:
- Continue treatment until two consecutive negative biopsies show no pathological changes 1
- Hysteroscopy-directed biopsy is preferred over blind sampling 1
- Transvaginal ultrasound should accompany each evaluation 1
When to Consider Hysterectomy
Hysterectomy is NOT the preferred initial treatment for hyperplasia without atypia 1. However, consider surgical management in these specific scenarios:
- Persistent disease after 12-18 months of adequate medical therapy 1
- Recurrent hyperplasia after initial successful treatment 1
- Contraindications to progestin therapy: active breast cancer, history of thromboembolic disease, acute liver disease 4, 5
- Patient preference after counseling on alternatives 1
- Presence of additional risk factors: obesity, diabetes, persistent abnormal bleeding despite treatment 6
Important Clinical Considerations
Risk Stratification
At age 46, this patient is perimenopausal, which carries specific implications:
- Lower progression risk to cancer compared to atypical hyperplasia (1-3% vs 8-29%) 7
- Obesity, diabetes, and PCOS increase risk of progression and should be addressed 8
- Unopposed estrogen exposure from any source must be eliminated 7
Common Pitfalls to Avoid
Do not perform hysterectomy as first-line treatment - this represents overtreatment for non-atypical hyperplasia 1, 6
Do not use oral progestins cyclically - continuous progestin therapy is required for regression 4, 5
Do not rely on Pap smears or endometrial thickness alone for follow-up - histologic confirmation via biopsy is mandatory 1
Do not discontinue treatment after first negative biopsy - require two consecutive negative results to confirm regression 1
Long-Term Management
After successful regression:
- Long-term surveillance is essential as recurrence rates approach 19% overall 9
- Annual endometrial sampling should continue, especially if risk factors persist 1
- Weight management and lifestyle modification are critical adjuncts 5
- Consider definitive hysterectomy if childbearing is complete and patient has multiple risk factors 6
Special Circumstances
If the patient has fertility desires (though less likely at age 46):
- LNG-IUS remains appropriate 1
- After achieving regression, assisted reproductive technology should be considered promptly 1
- Hysterectomy should be performed after childbearing completion 3
The evidence consistently demonstrates that conservative medical management with LNG-IUS provides excellent outcomes for simple endometrial hyperplasia without atypia, with hysterectomy reserved for treatment failures or specific contraindications to medical therapy.